Seikagaku Corporation
Q1 2027 Fiscal Year Consolidated Financial Summary (Japanese GAAP) [Consolidated]
Sales rose 1.2% year-on-year to 883 million yen, operating loss of 943 million yen, ordinary income of 108 million yen, quarterly net loss attributable to owners of the parent of 11 million yen. Segments report trends for Pharmaceuticals, LAL, Raw Materials, and Royalties. Full-year forecast for 2027 unchanged.
Key Figures
- Sales: 8,833百万円
- Operating loss: △943百万円
- Ordinary income: 108百万円
- Net income attributable to owners of the parent: △11百万円
- Total assets: 84,490百万円
- Equity ratio: 87.8%
AI要約
Overview of Results
For the first quarter cumulative period, sales were 8,833 million yen, up 1.2% YoY, remaining solid, but operating loss occurred due to higher manufacturing costs. Ordinary income was 108 million yen in positive territory, but quarterly net loss attributable to owners of the parent was 11 million yen. The pharmaceutical business faced declines in overseas drugs, while the LAL business contributed with favorable performance. Segment-wise, Pharmaceuticals and LAL comprised the majority of the total.
Financial Position and Outlook
Total assets were 84,490 million yen, liabilities 10,300 million yen, and net assets 74,189 million yen. Decreases in cash, deposits, and marketable securities affected figures. There were no changes to the consolidated full-year earnings forecast announced in May 2026, and the full-year outlook remains unchanged. Supplemental earnings materials have been disclosed. Going forward, R&D will continue to focus on new drug development and advancing alliances in the carbohydrate science field.
Biochemical Industry Co., Ltd.
Company overview · Stock price · Financial data · All IR
